Modern view on the problem of pelvic inflammatory disease in women

Abstract

The objective: to learn the efficacy of some fluoroquinolones II and III generation (combination drug Orcipol (ciprofloxacin with ornidazole) and Levoximed (levofloxacin) from World Medicine Pharmaceutical Company, UK) in the treatment of urogenital mixed infections in patients with pelvic inflammatory disease (PID) for vaginal sanitation and restoration of reproductive health. Patients and methods. A clinical examination and complex treatment of 50 patients of reproductive age for the first or second episode of PID of moderate severity was held. Patients of the 1st group (n=25) with mixed aerobic and anaerobic infections, Chlamydia were prescribed Levoximed for 7–14 days. Patients of the 2nd group (n=25) with mixed aerobic and anaerobic infections, bacterial vaginosis or trichomoniasis received a combined drug – Orcipol for 5–7 days. Results. The use of Levoximed and combined antibacterial therapy with Orcipol in the complex treatment of patients with PID was successful. The efficacy of Levoximed and Orcipol in the complex treatment of PID in the groups surveyed was comparable, and it was good in most cases – 92% in Group 1 and 88% in Group 2. Conclusions. The use of combined antibacterial therapy with the inclusion of drugs that overlap the spectrum of aerobic and anaerobic pathogens, protozoal sexually transmitted infections, is an important factor in the successful treatment of inflammatory diseases of the genitals in women. High clinical effectiveness of treatment with the use of drugs Levoximed and Orcipol in patients with PID can recommend them for widespread use in gynecological practice. Key words: pelvic inflammatory diseases, urogenital infections, Levoximed, Orcipol.